SCHEMBL20673453

SCHEMBL20673453

Cc1ccc(C(F)(F)F)cc1N1CCN(C(=O)C[C@@H](C)c2ccc(C(F)(F)F)nc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 13/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ FFAR4 Q5NUL3 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ STAT3 P40763 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ ACACB O00763 1/20 0.41
▸ PSEN1 P49768 1/20 0.41
▸ PSEN2 P49810 1/20 0.41
▸ APH1B Q8WW43 1/20 0.41
▸ NCSTN Q92542 1/20 0.41
▸ APH1A Q96BI3 1/20 0.41
▸ PSENEN Q9NZ42 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19403802 1.00 MC4R (0.44) MC4RSMN1; SMN2KDM4EL3MBTL1FFAR4
SCHEMBL26330641 0.88 L3MBTL1 (0.48) MC4RL3MBTL1FFAR4MEN1TSHR
SCHEMBL19403753 0.85 MC4R (0.45) MC4RL3MBTL1FFAR4MEN1TSHR
SCHEMBL20673523 0.83 MC4R (0.43) MC4RL3MBTL1FFAR4MEN1TSHR
SCHEMBL23549955 0.81 USP2 (0.55) MC4RSMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL19403828 0.81 USP2 (0.55) MC4RSMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL20673452 0.80 MC4R (0.59) MC4R
SCHEMBL23549989 0.79 MC4R (0.44) MC4RFFAR4MEN1TSHRKMT2A
SCHEMBL20673520 0.79 MC4R (0.45) MC4RL3MBTL1FFAR4MEN1TSHR
SCHEMBL19403746 0.78 L3MBTL1 (0.48) MC4RL3MBTL1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11766433-B2 Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-09-26 — — US disclosed
US-10980806-B2 Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-04-20 — — US disclosed
US-20190022093-A1 SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190022093-A1 SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AR, NR0B1, NCOA3 MC4R 3433/4885SMN1; SMN2 4769/4885KDM4E 2310/4885
US-11766433-B2 Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer AR, NR0B1, NCOA3 MC4R 3428/4885SMN1; SMN2 4767/4885KDM4E 2372/4885
US-10980806-B2 Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer AR, NR0B1, NCOA3 MC4R 3428/4885SMN1; SMN2 4767/4885KDM4E 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback